AZD1656
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glucose Lowering
Conditions
Glucose Lowering
Trial Timeline
Mar 1, 2010 → Oct 1, 2010
NCT ID
NCT01069926About AZD1656
AZD1656 is a phase 1 stage product being developed by AstraZeneca for Glucose Lowering. The current trial status is completed. This product is registered under clinical trial identifier NCT01069926. Target conditions include Glucose Lowering.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01221519 | Phase 1 | Completed |
| NCT01069926 | Phase 1 | Completed |
| NCT00819884 | Phase 1 | Completed |
| NCT00741689 | Phase 1 | Completed |
Competing Products
17 competing products in Glucose Lowering
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin + Alpha lipoic acid + Olmesartan + Placebo | Daiichi Sankyo | Pre-clinical | 23 |
| Exenatide + Metformin | Eli Lilly | Approved | 85 |
| Candesartan + Placebo | AstraZeneca | Approved | 85 |
| Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mg | Merck | Phase 2 | 52 |
| Sitagliptin-Metformin + Metformin + Placebo pill | Merck | Approved | 85 |
| Comparator: exenatide + Comparator: exenatide + Comparator: Placebo | Merck | Phase 1 | 33 |
| Placebo + Januvia | Merck | Phase 2 | 52 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| Ramipril + Rosiglitazone | Pfizer | Phase 3 | 76 |
| HSK7653 10mg Q2W + HSK7653 25mg Q2W + Placebo | Haisco Pharmaceutical Group | Phase 2 | 49 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| UX007 + Placebo | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| GFT505 80mg + Placebo | Genfit | Phase 2 | 44 |